Published in J Virol on November 01, 1988
Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis (2004) 2.96
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J (1990) 1.59
Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. J Virol (1991) 1.50
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol (1992) 1.34
Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol (2010) 1.21
Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol (2013) 1.15
Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol (2009) 1.13
Monoclonal antibody-based capture enzyme immunoassays for specific serum immunoglobulin G (IgG), IgA, and IgM antibodies to respiratory syncytial virus. J Clin Microbiol (1990) 1.13
Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol (1991) 1.09
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol (2009) 1.07
Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J Infect Dis (2012) 1.05
Differentiation of respiratory syncytial virus subgroups with cDNA probes in a nucleic acid hybridization assay. J Clin Microbiol (1990) 1.02
Novel antigens for RSV vaccines. Curr Opin Immunol (2015) 0.99
Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother (1994) 0.98
Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev (1995) 0.97
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol (2013) 0.95
Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol (2002) 0.95
Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol (2013) 0.93
Antibody enhancement of respiratory syncytial virus stimulation of leukotriene production by a macrophagelike cell line. J Virol (1991) 0.91
Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J Virol (1991) 0.90
Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog (2014) 0.90
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog (2015) 0.89
Antigenic characterization of respiratory syncytial virus group A and B isolates in Rio de Janeiro, Brazil. J Clin Microbiol (1991) 0.88
Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution? J Virol (2015) 0.86
A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. J Virol (2014) 0.86
Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus. Virol J (2007) 0.84
Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies. J Virol (1990) 0.83
An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology (2015) 0.82
Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. PLoS Pathog (2016) 0.81
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One (2012) 0.80
Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine (2014) 0.80
Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. PLoS One (2015) 0.80
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol (2016) 0.79
Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection. Comp Med (2012) 0.79
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol (2016) 0.78
Biochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseases. Virol J (2004) 0.78
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun (2016) 0.77
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology (2014) 0.77
Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein. PLoS One (2016) 0.77
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice. PLoS One (2013) 0.76
Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine (2016) 0.75
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One (2017) 0.75
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus. Yonsei Med J (2016) 0.75
Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model. Sci Rep (2017) 0.75
Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin. Nanomedicine (2015) 0.75
Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus. Clin Diagn Lab Immunol (1994) 0.75
Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods. BMC Infect Dis (2017) 0.75
Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective. J Virol (2017) 0.75
Antibody-induced internalization of the human respiratory syncytial virus fusion protein. J Virol (2017) 0.75
Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis (1985) 5.91
Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 5.19
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol (1983) 4.05
Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med (1986) 3.43
Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 3.27
Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg (1957) 3.24
Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol (1985) 2.87
Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res (1985) 2.42
Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol (1987) 2.41
Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health (1970) 2.30
Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol (1984) 2.30
Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol (1981) 2.26
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol (1986) 2.18
Antigenic differences between two strains of respiratory syncytial virus. Proc Soc Exp Biol Med (1963) 2.16
Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. J Virol (1987) 1.98
Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis (1976) 1.95
Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol (1985) 1.84
Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B. J Gen Virol (1987) 1.73
Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol (1982) 1.54
Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis (1987) 1.51
Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol (1987) 1.38
Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J Clin Microbiol (1986) 1.33
Classification of hybridomas to respiratory syncytial virus glycoproteins. Proc Soc Exp Biol Med (1982) 1.32
Experimental infection with respiratory syncytial virus in several species of animals. Am J Hyg (1962) 1.26
Epidemic bronchiolitis caused by a respiratory syncytial virus: clinical aspects. Med J Aust (1961) 1.14
Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections. J Med Virol (1980) 1.13
Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol (1986) 1.12
Viral epitopes and monoclonal antibodies: isolation of blocking antibodies that inhibit virus neutralization. Science (1981) 1.07
Serological studies with respiratory syncytial virus. Arch Gesamte Virusforsch (1965) 1.06
Cellular and humoral immunity in recurrent respiratory syncytial virus infections. Pediatr Res (1983) 0.94
Report of a workshop on respiratory syncytial virus and parainfluenza viruses. J Infect Dis (1983) 0.93
Enhanced neutralization of La Crosse virus by the binding of specific pairs of monoclonal antibodies to the G1 glycoprotein. Virology (1984) 0.92
Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis (1985) 5.91
Standardized viral hemagglutination and hemagglutination-inhibition tests. II. Description and statistical evaluation. Appl Microbiol (1969) 4.99
The relative risks of caesarean section (intrapartum and elective) and vaginal delivery: a detailed analysis to exclude the effects of medical disorders and other acute pre-existing physiological disturbances. Br J Obstet Gynaecol (1990) 3.96
Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol (1999) 3.35
Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. Appl Microbiol (1969) 3.19
Letter: Adenovirus type 19 keratoconjunctivitis. N Engl J Med (1974) 2.63
Adult pneumonia in a general hospital. Etiology and host risk factors. Arch Intern Med (1972) 2.24
DNA restriction analysis of adenovirus prototypes 1 to 41. Arch Virol (1986) 2.20
Coronaviridae: second report. Intervirology (1978) 2.05
Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol (1985) 1.84
Further subgrouping of the human adenoviruses by differential hemagglutination. J Infect Dis (1973) 1.77
Airways function during mild viral respiratory illnesses. The effect of rhinovirus infection in cigarette smokers. Ann Intern Med (1974) 1.72
Mapping of base sequence heterologies between genomes from different adenovirus serotypes. Virology (1973) 1.71
Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis (1990) 1.66
Protein composition of coronavirus OC 43. Virology (1972) 1.66
Management of the selected term breech presentation: assessment of the risks of selected vaginal delivery versus cesarean section for all cases. Obstet Gynecol (1987) 1.63
Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am J Epidemiol (1970) 1.60
Characteristics of noncultivable adenoviruses associated with diarrhea in infants: a new subgroup of human adenoviruses. J Clin Microbiol (1979) 1.56
The changing etiology of epidemic keratoconjunctivitis: antigenic and restriction enzyme analyses of adenovirus types 19 and 37 isolated over a 10-year period. J Infect Dis (1983) 1.51
Nonspecific precipitation of serum proteins by sodium lauryl sulfate in agar diffusion and immunoelectrophoresis. Appl Microbiol (1971) 1.37
New human adenovirus isolated from a renal transplant recipient: description and characterization of candiate adenovirus type 34. J Clin Microbiol (1975) 1.37
Epidemic keratoconjunctivitis. A severe industrial outbreak due to adenovirus type 8. N Engl J Med (1973) 1.37
Occurrence of respiratory illness due to an atypical strain of adenovirus type 11 during a large outbreak in Spanish military recruits. Am J Epidemiol (1974) 1.35
Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J Clin Microbiol (1986) 1.33
The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genet Test (1997) 1.33
Studies of stools from pseudomembranous colitis, rotaviral, and other diarrheal syndromes by frequency-pulsed electron capture gas-liquid chromatography. J Clin Microbiol (1984) 1.31
Vero microcultures for adenovirus neutralization tests. J Clin Microbiol (1978) 1.28
New human adenovirus (candidate adenovirus type 35) causing fatal disseminated infection in a renal transplant recipient. J Clin Microbiol (1977) 1.27
Epidemic keratoconjunctivitis: a community outbreak of mixed adenovirus type 8 and type 19 infection. J Infect Dis (1975) 1.27
Adenoviridae: second report. Intervirology (1982) 1.26
Reference equine antisera to 33 human adenovirus types: homologous and heterologous titers. J Clin Microbiol (1975) 1.25
Epidemic keratoconjunctivitis caused by adenovirus type 8: epidemiologic and laboratory aspects of a large outbreak. Am J Epidemiol (1981) 1.24
Purification and biophysical properties of human coronavirus 229E. Virology (1976) 1.21
Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water. J Infect Dis (1979) 1.21
Strengths and weaknesses of direct patient interviewing by a microcomputer system in specialist gynaecological practice. Eur J Obstet Gynecol Reprod Biol (1984) 1.20
Immunological basis of the adenovirus 8-9 cross-reaction. J Virol (1970) 1.19
The development of on-line history-taking systems in antenatal care. Methods Inf Med (1983) 1.18
Compulsory removal to and detention in hospital in the case of notifiable disease: a survey of public health doctors. Public Health (1993) 1.17
Quantitation of antibody to non-hemagglutinating viruses by single radial hemolysis: serological test for human coronaviruses. J Clin Microbiol (1977) 1.17
Astrovirus and adenovirus associated with diarrhea in children in day care settings. J Infect Dis (1991) 1.17
Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med (1975) 1.13
Antigenic characterization of intermediate adenovirus 14-11 strains associated with upper respiratory illness in a military camp. Infect Immun (1976) 1.11
Adenovirus types 2, 8, and 37 associated with genital infections in patients attending a sexually transmitted disease clinic. J Clin Microbiol (1995) 1.10
An outbreak of adenovirus type 3 disease at a private recreation center swimming pool. Am J Epidemiol (1980) 1.09
Characterization of adenovirus 15/H9 intermediate strains. Intervirology (1985) 1.09
A confidential enquiry into emergency hospital admissions on the Isle of Wight, UK. J Epidemiol Community Health (1997) 1.08
The effect of centrifugation on the rapid detection of adenovirus in shell vials. Am J Clin Pathol (1987) 1.07
New strain of mouse hepatitis virus as the cause of lethal enteritis in infant mice. Infect Immun (1979) 1.05
Serosurvey for "acute hemorrhagic conjunctivitis" virus (Enterovirus 70) antibodies in the Southeastern United States, with review of the literature and some epidemiologic implications. Am J Epidemiol (1975) 1.05
Use of a microcomputer network for history taking in a prenatal clinic. Am J Perinatol (1985) 1.05
Purification and further characterization of an "IBV-like" virus (coronavirus). Proc Soc Exp Biol Med (1970) 1.04
Production and evaluation of a purified adenovirus group-specific (hexon) antigen for use in the diagnostic complement fixation test. Appl Microbiol (1971) 1.04
Molecular epidemiology and restriction site mapping of adenovirus type 3 genome types. J Clin Microbiol (1989) 1.04
Molecular epidemiology and restriction site mapping of adenovirus 7 genome types. Arch Virol (1989) 1.03
Counterimmunoelectrophoresis with adenovirus type-specific anti-hemagglutinin sera as a rapid diagnostic method. J Immunol (1974) 1.03
Comparison of immunization methods for producing reference adenovirus antisera in horses. Appl Microbiol (1972) 1.02
Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention. Infect Control (1984) 1.01
Viral isolation studies of inclusion positive biopsy from human connective tissue diseases. Arthritis Rheum (1970) 1.00
Isolation of adenovirus type 34 from a renal transplant recipient with interstitial pneumonia. Transplantation (1977) 0.99
Oligonucleotide fingerprint analysis of enterovirus 70 isolates from the 1980 to 1981 pandemic of acute hemorrhagic conjunctivitis: evidence for a close genetic relationship among Asian and American strains. Infect Immun (1983) 0.99
Hemagglutination properties of adenovirus types 20, 25, and 28. Proc Soc Exp Biol Med (1970) 0.97
Immunological and biochemical characterization of human adenoviruses from subgenus B. I. Antigenic relationships. Arch Virol (1985) 0.97
Purification and properties of a glycoprotein acid phosphatase from Candida albicans. J Bacteriol (1973) 0.97
Genome analysis of adenovirus type 31 strains from immunocompromised and immunocompetent patients. J Infect Dis (1991) 0.96
Croup and pneumonia in human infants associated with a new strain of respiratory syncytial virus. J Infect Dis (1979) 0.96
Three adenovirus type 8 genome types defined by restriction enzyme analysis: prototype stability in geographically separated populations. J Clin Microbiol (1986) 0.95
Outcome of breech delivery at term. BMJ (1992) 0.94
Comparison of a monoclonal antibody with a polyclonal serum in an enzyme-linked immunosorbent assay for detecting adenovirus. J Clin Microbiol (1983) 0.94
Physicochemical and serological characteristics of respiratory virus fluorescein-isothiocyanate conjugates for fluorescent-antibody diagnosis. J Clin Microbiol (1975) 0.94
Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI. Neuroradiology (2003) 0.94
Immunological and biochemical characterization of human adenoviruses from subgenus B. II. DNA restriction analysis. Arch Virol (1985) 0.93
Clinical and laboratory evaluation of epidemic keratoconjunctivitis due to adenovirus types 8 and 19. Am J Ophthalmol (1976) 0.93
Clinical and immunologic responses in patients with viral keratoconjunctivitis. Am J Ophthalmol (1975) 0.92
NCI-H292 as an alternative cell line for the isolation and propagation of the human paramyxoviruses. Arch Virol (1990) 0.92
Keratoconjunctivitis associated with adenovirus type 37: an extended outbreak in an ophthalmologist's office. J Infect Dis (1983) 0.90
An "outbreak" of juvenile diabetes mellitus: consideration of a viral etiology. Am J Epidemiol (1974) 0.88
Presence of genomic polyadenylate and absence of detectable virion transcriptase in human coronavirus OC-43. J Gen Virol (1978) 0.87
Extrapulmonary manifestations of adenovirus type 7 pneumonia simulating Reye syndrome and the possible role of an adenovirus toxin. J Pediatr (1979) 0.87
New human adenovirus associated with respiratory illness: candidate adenovirus type 39. J Clin Microbiol (1982) 0.87
Generalized viral illness caused by an intermediate strain of adenovirus (21/H21 + 35). J Infect Dis (1980) 0.86
Use of the biotin-avidin system to study the specificity of antibodies against respiratory syncytial virus. J Clin Microbiol (1984) 0.86
Computerized histories facilitate patient care in a termination of pregnancy clinic: the use of a small computer to obtain and reproduce patient information. Br J Obstet Gynaecol (1985) 0.86
Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci (1992) 0.85
Acute hemorrhagic conjunctivitis: a mixed virus outbreak among Vietnamese refugees on Guam. Am J Epidemiol (1977) 0.85
Follow-up of children infected in a coxsackievirus B-3 and B-4 outbreak: no evidence of diabetes mellitus. J Infect Dis (1974) 0.84
The problems of tracing a geographically widespread outbreak of salmonellosis from a commonly eaten food: Salmonella typhimurium DT193 in north west England and north Wales in 1991. Epidemiol Infect (1993) 0.83
Peripheral ischaemia and gangrene presenting at birth. Eur J Pediatr (1992) 0.83
Acute hemorrhagic conjunctivitis in Southeast Asian refugees arriving in the United States--isolation of enterovirus 70. Am J Trop Med Hyg (1982) 0.83
Spectrophotometric quantitation of peroxidase-stained protein bands following gel electrophoresis and the western blot transfer technique with respiratory syncytial virus. J Virol Methods (1984) 0.83
Freeze-drying of respiratory syncytial viruses for transportation and storage. J Clin Microbiol (1987) 0.82
Sequence and functional analysis of the human adenovirus type 7 E3-gp19K protein from 17 clinical isolates. Virology (1993) 0.81
Lethal enteritis in infant mice caused by mouse hepatitis virus. Lab Anim Sci (1976) 0.81
Contamination of primary embryonic bovine kidney cell cultures with parainfluenza type 2 simian virus 5 and infectious bovine rhinotracheitis virus. J Clin Microbiol (1978) 0.81
Neonatal pulmonary insufficiency caused by adenovirus infection successfully treated with extracorporeal membrane oxygenation. J Pediatr (1994) 0.81
Application of a solid-phase immunofluorometric assay to the selection of monoclonal antibody specific for the adenovirus group-reactive hexon antigen. Arch Virol (1984) 0.81
Necrotizing pancreatitis due to simian adenovirus type 31 in a rhesus monkey. Arch Pathol Lab Med (1978) 0.81
Respiratory syncytial virus: a review of the virus, its epidemiology, immune response and laboratory diagnosis. Aust Paediatr J (1986) 0.80
Herpes type 2 infection with unusual generalised manifestations and delayed diagnosis in an adult male. J Infect (1983) 0.80
Antigenically intermediate human adenovirus strain associated with conjunctivitis. J Clin Microbiol (1981) 0.80